Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 4/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189304 | 1.00 | BLM (0.32) | BLMPMP22HSD17B10LTA4HCA12 | |
| SCHEMBL21189165 | 0.99 | BLM (0.33) | BLMPMP22HSD17B10LTA4HCA12 | |
| SCHEMBL21189283 | 0.99 | BLM (0.33) | BLMPMP22HSD17B10LTA4HCA12 | |
| SCHEMBL21189288 | 0.99 | BLM (0.33) | BLMPMP22HSD17B10LTA4HCA12 | |
| SCHEMBL19406683 | 0.89 | MEN1 (0.35) | CA12CA1CA7CA14 | |
| SCHEMBL20158521 | 0.80 | EPHX2 (0.39) | — | |
| SCHEMBL8374138 | 0.80 | MEN1 (0.39) | CA12CA1CA7CA14 | |
| SCHEMBL5494091 | 0.80 | APLNR (0.40) | CA12CA1CA7CA14 | |
| SCHEMBL18906915 | 0.77 | APLNR (0.37) | CA12CA1CA7CA14 | |
| SCHEMBL18906911 | 0.77 | APLNR (0.37) | CA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | MTOR, PIK3CA, MAPKAP1 | BLM 2154/4885PMP22 2856/4885HSD17B10 3461/4885 |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | MTOR, PIK3CA, MAPKAP1 | BLM 2154/4885PMP22 2856/4885HSD17B10 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.